{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Crew KD"],"funding":["American Society of Clinical OncologyAmerican Society of Clinical Oncology (ASCO)","NCI NIH HHS","HHS | NIH | National Cancer InstituteHHS | NIH | National Cancer Institute (NCI)"],"pagination":["481-490"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6609474"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(7)"],"pubmed_abstract":["Observational studies have reported an inverse association between vitamin D intake and breast cancer risk. We examined whether vitamin D supplementation in high-risk premenopausal women reduces mammographic density (MD), an established breast cancer risk factor. We conducted a multicenter randomized double-blind placebo-controlled trial in premenopausal women at high risk for breast cancer [5-year risk ≥ 1.67%, lifetime risk ≥ 20%, lobular carcinoma <i>in situ</i>, prior stage 0-II breast cancer, hereditary breast cancer syndrome, or high MD (heterogeneously/extremely dense)], with a baseline serum 25-hydroxyvitamin D [25(OH)D] ≤ 32 ng/mL. Participants were randomized to 12 months of vitamin D3 20,000 IU/week or matching placebo. The primary endpoint was change in MD from baseline to 12 m"],"journal":["Cancer prevention research (Philadelphia, Pa.)"],"pubmed_title":["Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812)."],"pmcid":["PMC6609474"],"funding_grant_id":["N/A","U10 CA180819","UG1 CA233329","UG1 CA190002","UG1 CA189953","P30 CA016672","UG1 CA189974","UG1 CA189830","UG1 CA189960","UG1CA189974","U10 CA180828","U10 CA180858","UG1 CA189858"],"pubmed_authors":["Ford L","Bevers T","Kruper L","Arun B","Goodman GE","Hershman DL","Minasian LM","Tehranifar P","Kairouz SS","Doster JE","Anderson GL","Terry MB","Yee M","Kuwajerwala N","Zarwan C","Crew KD","Neuhouser M","Brown EA","Lew DL","Brown PH"],"additional_accession":[]},"is_claimable":false,"name":"Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812).","description":"Observational studies have reported an inverse association between vitamin D intake and breast cancer risk. We examined whether vitamin D supplementation in high-risk premenopausal women reduces mammographic density (MD), an established breast cancer risk factor. We conducted a multicenter randomized double-blind placebo-controlled trial in premenopausal women at high risk for breast cancer [5-year risk ≥ 1.67%, lifetime risk ≥ 20%, lobular carcinoma <i>in situ</i>, prior stage 0-II breast cancer, hereditary breast cancer syndrome, or high MD (heterogeneously/extremely dense)], with a baseline serum 25-hydroxyvitamin D [25(OH)D] ≤ 32 ng/mL. Participants were randomized to 12 months of vitamin D3 20,000 IU/week or matching placebo. The primary endpoint was change in MD from baseline to 12 m","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Jul","modification":"2026-04-12T23:53:47.071Z","creation":"2025-05-29T21:30:39.351Z"},"accession":"S-EPMC6609474","cross_references":{"pubmed":["31138522"],"doi":["10.1158/1940-6207.capr-18-0444","10.1158/1940-6207.CAPR-18-0444"]}}